^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy + Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety analysis of immune checkpoint inhibitors plus angiogenesis inhibitors for treatment of advanced driver-negative NSCLC in elderly patients: A retrospective study.
Published date:
05/25/2023
Excerpt:
A total of 36 patients in the IA group (Immune checkpoint inhibitors plus angiogenesis inhibitors group)...were enrolled in the study....Subgroup analysis showed that patients in the IA group had significantly longer PFS in the subgroup with PD-L1 expression ≥50% (P = 0.017)….In the subgroup analysis, we found that the clinical benefit of this combination therapy was observed in patients with PD-L1 expression ≥50%...
DOI:
10.1200/JCO.2023.41.16_suppl.e21044
Trial ID:
Source:
Title:
Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
Published date:
05/19/2023
Excerpt:
Data on clinicopathological features, efficacy and adverse events (AEs) were collected retrospectively in advanced NSCLC patients who received immunotherapy combined with antiangiogenic therapy....NSCLC patients with high PD-L1 expression were more likely to respond to combination therapy and had longer PFS and OS.
DOI:
https://doi.org/10.1186/s12890-023-02470-z
